For decades, Sjögren's disease had zero FDA-approved treatments that target the actual disease. Amgen's dazodalibep just delivered a clean Phase 3 win in 651 patients, and the race to build an entirely new market is officially on.
Imagine going to the doctor and being told: "Yes, your immune system is attacking your own body. No, we don't really have a drug for that. Here's some eye drops."
That's been the reality for millions of people living with Sjögren's disease, a chronic autoimmune condition that dries out your eyes, your mouth, and your energy levels, while quietly damaging organs in the background. For decades, treatment has meant managing symptoms with artificial tears, saliva substitutes, and borrowed drugs from other conditions. No FDA-approved therapy has ever targeted the actual disease.
Until, possibly, now.
A $27.8 Billion Bet Starts Paying Off
Amgen just reported that its drug dazodalibep (also known as HZN-4920) hit its primary endpoint in a Phase 3 trial called OASIZ 301. The study enrolled approximately 621 patients with moderate-to-severe Sjögren's disease, and the drug showed statistically significant improvement in disease severity at 48 weeks. Patients started getting better as early as week four, and the improvement held steady through the full year of treatment.
Amgen didn't develop this drug from scratch. It inherited dazodalibep through its $27.8 billion acquisition of Horizon Therapeutics, which closed in October 2023. Horizon had picked up the molecule from Viela Bio in 2021, and Viela had gotten it from AstraZeneca before that. This drug has had more owners than a used car on Craigslist, but it finally landed in a company with the resources to push it across the finish line.
Amgen's stock climbed about 4% on the news. Not a moonshot, but a meaningful signal that Wall Street is paying attention.
What Sjögren's Actually Does (and Why It's So Hard to Treat)
Sjögren's is one of those diseases that sounds mild until you understand what's really happening. Your immune system mistakes your moisture-producing glands for foreign invaders and slowly destroys them. The hallmark symptoms are severe dryness in the eyes and mouth, but the disease often goes deeper: joint pain, crushing fatigue, and inflammation that can affect the lungs, kidneys, and nervous system.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
It's also surprisingly common. Prevalence estimates range from roughly 0.1% to 1% of the population depending on how you define it, which puts it in the same neighborhood as better-known autoimmune conditions. Yet while diseases like rheumatoid arthritis and lupus have entire drug classes built around them, Sjögren's patients have been stuck with pilocarpine and cevimeline (drugs that stimulate saliva production) and off-label use of immunosuppressants like hydroxychloroquine, which has limited evidence of actually working.
The standard of care, in other words, has been a collection of band-aids. Nobody had a therapy that goes after the root cause.
The Science: Cutting the Phone Line Between Immune Cells
To understand why dazodalibep matters, you need to know one thing about your immune system: T cells and B cells talk to each other. A lot. One of their favorite communication channels is a molecular handshake called the CD40-CD40L pathway. When an activated T cell extends a protein called CD40L, it grabs onto CD40 on the surface of a B cell. That handshake tells the B cell to wake up, multiply, and start producing antibodies.
In autoimmune diseases like Sjögren's, this conversation goes haywire. The handshake happens too often, B cells get overstimulated, and they start churning out antibodies that attack your own tissues.
Dazodalibep works by blocking CD40L before it can grab CD40. Think of it like jamming a phone signal: the T cell is trying to call the B cell, but dazodalibep intercepts the signal. No call, no overreaction.
What makes this drug clever is its design. Previous attempts to block CD40L used traditional antibodies, but those triggered a nasty side effect: dangerous blood clots, because platelets also carry CD40L. Dazodalibep sidesteps this problem entirely. It's built as a fusion protein (not an antibody), and it deliberately lacks the Fc region that activates platelets. In the OASIZ 301 trial, there was no imbalance in blood clot events between the drug and placebo. The most common side effects were garden-variety stuff: common colds, urinary tract infections, and mild infusion reactions.
The Market Nobody Built
This is where the business story gets interesting. When there are zero approved disease-modifying therapies for a condition, whoever gets there first essentially creates the market from nothing. There's no competitor to steal share from; there's only an ocean of unmet need.
But Amgen won't have the CD40L space to itself for long. Sanofi's frexalimab is racing through Phase 2/3 trials in multiple sclerosis, with broader autoimmune ambitions. Dapirolizumab pegol is in Phase 3 for lupus. And a handful of earlier-stage programs (iscalimab, tegoprubart, TNX-1500) are targeting the same pathway for transplant rejection and other immune conditions.
The difference is that none of those competitors are targeting Sjögren's with late-stage data in hand. Amgen has a genuine first-mover advantage here, at least for now.
What Wall Street Thinks (and What's Missing)
Despite the clean Phase 3 win, analyst reactions have been measured. The consensus rating on Amgen remains Hold, with average price targets hovering around $381 to $389. Oppenheimer is more bullish at $450.
The caution makes sense for one reason: Amgen hasn't released the actual numbers yet. We know the trial "met its primary endpoint" and that improvements were "statistically significant and clinically meaningful," but we don't know the exact magnitude of benefit, the p-value, or how big the gap was between drug and placebo. Citi noted that the result reduces clinical risk for a "potentially underappreciated asset," but said the competitive profile remains an open question until fuller data drop.
There's also a second pivotal trial, OASIZ 303, that still needs to read out before Amgen can assemble a complete regulatory package. One win is encouraging; two wins would be the real green light.
Why This Matters Beyond the Stock Price
For Sjögren's patients, this isn't about Amgen's pipeline strategy or analyst price targets. It's about the possibility that, for the first time ever, there might be a drug designed to treat their actual disease, not just its symptoms.
Amgen paid $27.8 billion for Horizon, and dazodalibep was one of the crown jewels in that deal. This Phase 3 result suggests the jewel is real. The full data will tell us how brightly it shines.
Deals & M&A4 min read
Novartis Just Paid Up to $900M for a Drug That Doesn't Exist Yet
Novartis just committed up to $900 million for a preclinical radioligand therapy from China's Boomray Pharmaceuticals, and nobody even knows what the drug targets. With Big Pharma's radioligand arms race heating up and geopolitical tensions simmering, this mystery deal says a lot about where oncology is headed.
